Ignite Creation Date:
2025-12-26 @ 5:19 PM
Ignite Modification Date:
2026-01-22 @ 8:21 AM
Study NCT ID:
NCT07159906
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-09-08
First Post:
2025-08-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sponsor:
First Affiliated Hospital of Zhejiang University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-09-08
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-08-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-08-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-08-17
First Submit QC Date:
None
Study First Post Date:
2025-09-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-04
Last Update Post Date:
2025-09-08
Last Update Post Date Type:
ESTIMATED